Should I Buy ORIC? ORIC 2026 Analysis

Should You Buy Oric Pharmaceuticals Inc (ORIC) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

10.760

1 Day change

-2.00%

52 Week Range

14.930

Analysis Updated At

2026/01/26

Oric Pharmaceuticals Inc (ORIC) is not a strong buy for a beginner, long-term investor at this time. While the company has promising developments in its pipeline, the lack of strong financial performance, hedge fund selling trends, and absence of immediate positive catalysts suggest holding off on investment until further updates, such as the Q1 2026 clinical update for ORIC-944.

Technical Analysis

The MACD is positive at 0.426 but contracting, indicating weakening bullish momentum. RSI at 73.913 is neutral, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R1: 12.377), suggesting limited upside in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The Q1 2026 clinical update is expected to be a significant catalyst.

Neutral/Negative Catalysts

Hedge funds have significantly increased selling activity (up 496.64% last quarter). Financial performance is weak, with no revenue, a net income loss of -$32.59M, and a YoY EPS decline of -32.65%. No recent news or congress trading data to support a buy.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income dropped by -5.73% YoY to -$32.59M, and EPS declined by -32.65% YoY to -0.33. The company is not yet profitable, and its financials show no signs of improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are generally bullish, with multiple Overweight/Outperform ratings and price targets ranging from $15 to $25. Piper Sandler and others see potential in ORIC-944 as a best-in-class PRC2 inhibitor for prostate cancer. However, no immediate catalysts are present until Q1 2026.

12 Analyst Rating

Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 19.6 USD with a low forecast of 15 USD and a high forecast of 25 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

1 Hold

0 Sell

Strong Buy

Current: 10.980

Low

Averages

19.6

High

Current: 10.980

Low

Averages

19.6

High

Piper Sandler

Kelsey Goodwin

Overweight

initiated

$22

AI Analysis

2026-01-07

Reason

Piper Sandler

Kelsey Goodwin

Price Target

$22

AI Analysis

2026-01-07

initiated

Overweight

Reason

Piper Sandler analyst Kelsey Goodwin initiated coverage of Oric Pharmaceuticals with an Overweight rating and $22 price target. The company's ORIC-944 is a potential best-in-class PRC2 inhibitor capable of becoming a standard of care treatment class in prostate cancer, the analyst tells investors in a research note. Piper believes the ORIC-944 clinical update in Q1 "is likely to represent a value creation event."

Wells Fargo

Overweight

upgrade

$19 -> $25

2025-12-08

Reason

Wells Fargo

Price Target

$19 -> $25

2025-12-08

upgrade

Overweight

Reason

Wells Fargo raised the firm's price target on Oric Pharmaceuticals to $25 from $19 and keeps an Overweight rating on the shares. While enozertinib has largely taken a back seat to ORIC-944, its data presented at ESMO Asia is intriguing and Wells thinks enough for investors to start assigning more credit. The firm believes shares should trade up.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ORIC

Unlock Now

ORIC Should I Buy

ORIC Should I Buy

Should You Buy Oric Pharmaceuticals Inc (ORIC) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch